About: Lampalizumab

Property	Value
dbo:abstract	لامباليزوماب جسم مضاد وحيد النسيلة مأنسن طورته /روش حيث إن مصمم لعلاج الظمور الجغرافي الثانوي للتنكس البقعي المرتبط بالسن. (ar) Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration. One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point. The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point. These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy. (en)
dbo:casNumber	1278466-20-8
dbo:fdaUniiCode	UWU93Y99R3
dbo:kegg	D10440
dbo:wikiPageID	38166242 (xsd:integer)
dbo:wikiPageLength	3050 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	981891354 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Age-related_macular_degeneration dbc:Abandoned_drugs dbr:Drug_development dbr:Retinal_pigment_epithelium dbr:Atrophy dbr:International_Nonproprietary_Name dbc:Monoclonal_antibodies dbr:Complement_factor_D dbr:Intravitreal
dbp:atcPrefix	none (en)
dbp:c	2068 (xsd:integer)
dbp:casNumber	1278466 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	3214 (xsd:integer)
dbp:iupharLigand	8294 (xsd:integer)
dbp:kegg	D10440 (en)
dbp:mabType	Fab (en)
dbp:n	546 (xsd:integer)
dbp:o	676 (xsd:integer)
dbp:routesOfAdministration	dbr:Intravitreal
dbp:s	13 (xsd:integer)
dbp:source	zu/o (en)
dbp:target	dbr:Complement_factor_D
dbp:type	mab (en)
dbp:unii	UWU93Y99R3 (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Monoclonals_for_immune_system dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Abandoned_drugs dbc:Monoclonal_antibodies
gold:hypernym	dbr:Fragment
rdf:type	owl:Thing dbo:Place dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	لامباليزوماب جسم مضاد وحيد النسيلة مأنسن طورته /روش حيث إن مصمم لعلاج الظمور الجغرافي الثانوي للتنكس البقعي المرتبط بالسن. (ar) Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration. One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point. The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point. (en)
rdfs:label	لامباليزوماب (ar) Lampalizumab (en)
owl:sameAs	freebase:Lampalizumab yago-res:Lampalizumab wikidata:Lampalizumab dbpedia-ar:Lampalizumab https://global.dbpedia.org/id/4pppB
prov:wasDerivedFrom	wikipedia-en:Lampalizumab?oldid=981891354&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Lampalizumab
is dbo:wikiPageWikiLink of	dbr:List_of_therapeutic_monoclonal_antibodies
is foaf:primaryTopic of	wikipedia-en:Lampalizumab